Adicet Bio, Inc. Contract Liability (Deferred Revenue)
Adicet Bio, Inc. (ACET) had Contract Liability (Deferred Revenue) of $0 as of 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-15
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-09-30: Contract with Customer, Liability, Current $0.00.
- 2022-06-30: Contract with Customer, Liability, Current $0.00.
- 2022-03-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $4.80M 10-K · filed 2023-03-15 |
| 2021-09-30 | $10.09M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $13.15M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $17.96M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $13.98M 10-K · filed 2022-03-15 |
| 2020-09-30 | $19.39M 10-Q · filed 2020-11-05 |
| 2019-12-31 | $10.99M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |